Washington University -- St. Louis
Welcome,         Profile    Billing    Logout  
 6 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wong, Michael
NCT06291857: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

Not yet recruiting
3
9320
RoW
CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, COVID-19 and influenza combination, Novavax COVID-19 Vaccine, Novavax SARS-CoV-2 rS vaccine, tNIV Vaccine, Trivalent Nanoparticle Influenza Hemagglutinin Vaccine, Fluzone High Dose, Fluzone HD
Novavax
COVID-19
02/25
02/26
NCT03997435: FOLFOXIRI With or Without Intensification for Rectal Cancer

Recruiting
2
72
RoW
Control arm, Experimental arm
CCTU
Rectal Cancer
12/25
12/26
NCT06281678: A Study of IBI363 in Subjects with Advanced Solid Malignancies

Recruiting
2
178
US
IBI363
Innovent Biologics (Suzhou) Co. Ltd.
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
03/26
12/26
KEYNOTE-C86, NCT04993677 / 2021-002037-42: A Study of SEA-CD40 Given With Other Drugs in Cancers

Active, not recruiting
2
77
Europe, Canada, US
SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Carcinoma, Non-Small- Cell Lung
01/24
10/25
IGNYTE, NCT03767348 / 2016-004548-12: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Hourglass Jan 2024 - Mar 2024 : Data from IGNYTE trial in combination with Opdivo for 2L melanoma
Checkmark From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Nov 2020 - Nov 2020: From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Checkmark Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Nov 2019 - Nov 2019: Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Recruiting
2
340
Europe, US
RP1, nivolumab, Opdivo
Replimune Inc., Bristol-Myers Squibb
Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
12/25
12/28
TSC-STEPS, NCT05104983: Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study

Recruiting
2
64
US
Sirolimus, Placebo
Darcy Krueger
Tuberous Sclerosis Complex, Epilepsy
06/25
06/26
NCT06680128: A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

Not yet recruiting
1/2
402
RoW
GBP560-A, GBP560-B, IXIARO, IMOJEV, Normal Saline (Placebo)
SK Bioscience Co., Ltd.
Japanese Encephalitis Virus Disease
06/26
03/28
NCT05620940: A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.

Recruiting
1
40
RoW
Vivitrol Injectable Product, IVL3004, IVL4002
Inventage Lab., Inc.
Opioid Dependence, Alcohol Dependence
05/25
05/25
NCT05831995: Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.

Terminated
1
12
US
ABM-168
ABM Therapeutics Corporation
Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
06/24
06/24
NCT05676099: TSC Biosample Repository and Natural History Database

Recruiting
N/A
5000
Canada, US
Phlebotomy, Buccal (cheek) swab, Genetic Testing, Tissue donation after routine clinical procedure
National Tuberous Sclerosis Association
Tuberous Sclerosis, Lymphangioleiomyomatosis
12/50
12/50
Novak, Olga
NEOS, NCT04926818 / 2020-002700-39: Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Active, not recruiting
3
129
Europe, Canada, US, RoW
Fingolimod, FTY720, Ofatumumab, OMB157, Siponimod, BAF312, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Multiple Sclerosis (MS)
03/27
11/31
TSC-STEPS, NCT05104983: Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study

Recruiting
2
64
US
Sirolimus, Placebo
Darcy Krueger
Tuberous Sclerosis Complex, Epilepsy
06/25
06/26
ICCRN, NCT05558371: International CDKL5 Clinical Research Network

Recruiting
N/A
1000
US, RoW
No intervention.
University of Colorado, Denver, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), International Foundation for CDKL5 Research
CDKL5, CDKL5 Deficiency Disorder, CDD
02/26
02/27

Download Options